Corcept Therapeutics (CORT) Total Debt (2012 - 2017)

Corcept Therapeutics has disclosed Total Debt across 6 years of filings, most recently posting $4.6 million for Q2 2017.

• Total Debt for Q2 2017 came in at $4.6 million, down 79.49% year-over-year; the trailing twelve-month figure through Jun 2017 was $4.6 million (down 79.49% YoY), and the FY2016 annual result was $14.7 million, down 46.66% from the prior year.
• Total Debt came in at $4.6 million for Q2 2017 at Corcept Therapeutics, down from $10.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $35.1 million in Q1 2014 to a low of $4.6 million in Q2 2017.
• The 5-year median for Total Debt is $32.1 million (2015), against an average of $27.3 million.
• Across the five-year window, Total Debt rose 13.3% in 2013 and plunged 79.49% in 2017, its largest moves.
• Corcept Therapeutics' Total Debt stood at $35.1 million in 2013, then dropped by 3.36% to $33.9 million in 2014, then dropped by 18.87% to $27.5 million in 2015, then sank by 46.66% to $14.7 million in 2016, then plunged by 68.81% to $4.6 million in 2017.
• The last three Total Debt figures came in at $4.6 million (Q2 2017), $10.1 million (Q1 2017), and $14.7 million (Q4 2016), per Business Quant data.